Companies Investors People

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Lycia Therapeutics›

Library

Lycia Therapeutics

Leading in extracellular protein degradation with our innovative LYTAC platform.

South San Francisco, CA, US🇺🇸

Founded

Lycia Therapeutics Website, Blog & Press Pages - aVenture

Lycia Therapeutics - Library

lyciatx.comCrawled Oct 15, 2026

Topics

Publication type

Search the library

Content origin

Row density

Press

1 page

News/news

Careers & Hiring

1 page

Careers/careers
Lycia says its team brings experience across functional areas and shares values it considers important to its success.

Team

1 page

Team/about/team
Aetna Wun Trombley, Ph.D., has been Lycia’s president and CEO and a board member since April 2020. She was an independent director of Carmot Therapeutics from 2016 until Roche acquired it in 2024 and held leadership roles at NGM Biopharmaceuticals for nine years.

About

4 pages

About/about
Investors/about/investors
Overview/about/overview
Lycia is developing therapeutics to eliminate disease-causing extracellular proteins. Its platform is designed to produce LYTACs that bind target proteins and transport them into cells for degradation by lysosomes.
Partnering/about/partnering
Lycia works with partners to discover and develop LYTAC therapeutics. Its modular platform is designed to generate candidates across multiple disease areas rapidly and efficiently.

Contact

1 page

Contact/contact
Lycia’s corporate office is at 400 East Jamie Court, Suite 200, South San Francisco, CA 94080. The page lists phone and email contacts for general, partnering, and media inquiries.

Homepage

1 page

Homepage/
Lycia’s platform builds on research into LYTAC degraders, a class of therapeutics targeting dysregulated proteins in blood or on the outside of cells.

Privacy

1 page

Privacy Policy/privacy-policy
Lycia Therapeutics is a clinical-stage biotechnology company discovering and developing therapeutics that degrade extracellular and membrane-bound proteins. Its website provides information about the company and its product development activities.